News | Radiology Business | March 13, 2024

Lunit has announced a significant update on its acquisition of Volpara Health Technologies.

Lunit has announced a significant update on its acquisition of Volpara Health Technologies.

Lunit, a South Korea-based artificial intelligence (AI) solution provider focused on cancer diagnostics and therapeutics, has announced a significant update on its acquisition of Volpara Health Technologies, the Wellington, New Zealand-based developer of AI-enabled software for personalized screening and early detection of breast cancer. An initial order from the High Court of New Zealand has been granted, and all necessary consents under New Zealand's Overseas Investment Act and Overseas Investment Regulations have been secured to facilitate the implementation of the Scheme. Image courtesy: Lunit


March 13, 2024 — Lunit, a South Korea-based provider of AI-powered solutions for cancer diagnostics and therapeutics, has announced a significant update on its acquisition of Wellington, New Zealand-based Volpara Health Technologies Ltd., which provides AI-enabled software for personalized screening and early detection of breast cancer. An initial order from the High Court of New Zealand has been granted, and all necessary consents under New Zealand's Overseas Investment Act and Overseas Investment Regulations have been secured to facilitate the implementation of the Scheme. The initial order signals approval and mandates the upcoming shareholder meeting as the next step. Additional details released by Lunit in a written statement shared today follow.

The Scheme, which involves Lunit acquiring all of Volpara's shares at a price of AUD 1.15 (USD 0.76) per share, is now set to progress to a shareholder meeting. Volpara shareholders are invited to attend the Scheme meeting scheduled for April 12, 2024. During this meeting, shareholders will cast their votes on the proposed acquisition.

Should Volpara shareholders endorse the Scheme, Lunit will proceed to acquire the entire shareholding at the agreed price. This acquisition encompasses a total of 254 million shares, amounting to a substantial deal valued at about AUD 292 million (USD 193 million). The takeover is expected to be finalized by May 2024, marking a pivotal moment in Lunit's global expansion and commitment to conquer cancer through AI.

"We're pleased to announce the High Court's approval, a significant step in our remarkable journey. As we approach the final stage where Volpara's shareholders will cast their votes, I would also like to share that our funding for this acquisition is progressing seamlessly, ensuring everything is on track," said Brandon Suh, CEO of Lunit. Suh added, "We are confident that the synergies between Lunit and Volpara will create a powerful force in advancing AI-driven solutions for the benefit of cancer care professionals and patients worldwide."

The acquisition is poised to position Lunit as a leading force in the American market, leveraging Volpara's mammography solutions operational in over 2,000 U.S. medical sites. Additionally, Volpara's repository of over 100 million high-quality mammography images significantly contributes to enhancing Lunit's AI-powered solutions and laying the foundation for the development of autonomous AI models in the future.

In its written statement, Lunit noted that after receiving FDA clearance and the CE Mark, its flagship Lunit INSIGHT suite is clinically used in approximately 3,000+ hospitals and medical institutions across 40+ countries. Lunit is headquartered in Seoul, South Korea, with offices and representatives worldwide.

Volpara Health Technologies offers AI-powered image analysis enabling radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality. The company further notes that, in an industry facing increasing staff shortages, its software helps streamline operations and provides key performance insights that support continuous quality improvement.

A Certified B Corporation, Volpara maintains the most rigorous security certifications and holds over 100 patents and numerous regulatory registrations, including FDA clearance and CE marking. Volpara is based in Wellington, New Zealand, with an office in Seattle, WA.

More information: www.lunit.io, www.volparahealth.com

Related content:

Lunit to Acquire Volpara: Scheme Implementation Agreement Signed


Related Content

News | Ultrasound Imaging

April 22, 2024 — GE HealthCare announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which ...

Time April 22, 2024
arrow
News | Artificial Intelligence

April 19, 2024 — Large language model GPT-4 matched the performance of radiologists in detecting errors in radiology ...

Time April 22, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Radiology Business

April 17, 2024 — VISTA.AI announced the appointment of Daniel Hawkins as President and CEO. The company is pioneering AI ...

Time April 17, 2024
arrow
News | Mammography

April 16, 2024 — The Radiological Society of North America (RSNA) and GE HealthCare announced their collaboration to ...

Time April 16, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time April 15, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Dose Management

April 11, 2024 — Prelude Corporation (PreludeDx), a leader in precision diagnostics for early-stage breast cancer ...

Time April 11, 2024
arrow
Subscribe Now